PNLIP and obesity disorder: Although not as efficient or significant as orlistat and acarbose, ACH effectively inhibited pancreatic lipase, α-amylase, and α-glucosidase within a specific concentration range, providing optimism for its potential use as an anti-obesity and anti-diabetic agent in the future.